Lack of association between TGF-beta-1 genotypes and microalbuminuria in essential hypertensive men.

BACKGROUND Polymorphisms within the gene for transforming growth factor (TGF)-beta-1, a pro-fibrogenic cytokine pathophysiologically involved in hypertension and hypertensive target damage, might modulate the biological activity of the encoded protein. Through that mechanism, they might contribute to microalbuminuria, a marker of subclinical renal damage and a correlate of systemic inflammation and endothelial dysfunction in hypertension, a possibility never before tested. For this reason, we assessed the association of four TGF-beta-1 polymorphic variants (C-509T, Leu(10)-->Pro, Arg(25)-->Pro, Thr(263)-->Ile) with albuminuria in uncomplicated essential hypertensive men, using (circulating active + acid-activatable latent) TGF-beta-1 levels as an indirect index of their in vivo biological activity. Because of the close pathophysiological link of TGF-beta-1 with the renin-angiotensin system, we also tested the behaviour of the angiotensin converting enzyme (ACE) deletion/insertion (D/I) polymorphism. METHODS Albuminuria (three overnight collections), office and 24-h BP, left ventricular mass index (LVMI), BMI, renal function, glucose, lipids, plasma TGF-beta-1 (n = 162, ELISA) were measured in 222 genetically unrelated, never-treated, uncomplicated Caucasian hypertensive men. ACE D/I polymorphisms were analysed by the polymerase chain reaction technique or a 5' nuclease assay with further restriction analysis when required. RESULTS Urine albumin levels or microalbuminuria (albuminuria > or =15 microg/min) did not differ by TGF-beta-1 genotypes, but both parameters were more frequent in ACE D/D homozygotes. Plasma TGF-beta-1 was similar across genetic backgrounds and was unrelated to albuminuria. Cardiovascular, renal, metabolic parameters were homogeneously distributed across genotypes. CONCLUSIONS In contrast to its link with the ACE D/I genotype, microalbuminuria was independent of TGF-beta-1 polymorphism in this group of never-treated, uncomplicated essential hypertensive men.

[1]  M. Chan-yeung,et al.  Genetic polymorphisms and plasma levels of transforming growth factor-beta(1) in Chinese patients with tuberculosis in Hong Kong. , 2007, Cytokine.

[2]  S. Del Prato,et al.  Lack of association between endothelial nitric oxide synthase gene polymorphisms, microalbuminuria and endothelial dysfunction in hypertensive men , 2007, Journal of hypertension.

[3]  D. Grainger.  TGF-β and atherosclerosis in man , 2007 .

[4]  D. Cusi,et al.  α-Adducin and angiotensin-converting enzyme polymorphisms in hypertension: evidence for a joint influence on albuminuria , 2006, Journal of hypertension.

[5]  Marta Ruiz-Ortega,et al.  Renal and vascular hypertension-induced inflammation: role of angiotensin II , 2006, Current opinion in nephrology and hypertension.

[6]  Mark I McCarthy,et al.  What makes a good genetic association study? , 2005, The Lancet.

[7]  D. Cha,et al.  Urinary concentration of transforming growth factor‐β‐inducible gene‐h3(βig‐h3) in patients with Type 2 diabetes mellitus , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[8]  W. Scott,et al.  The TGF‐β1 gene codon 10 polymorphism contributes to the genetic predisposition to nephropathy in Type 1 diabetes , 2005 .

[9]  S. Del Prato,et al.  Low-Grade Inflammation and Microalbuminuria in Hypertension , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[10]  David J. Grainger.  Transforming Growth Factor β and Atherosclerosis: So Far, So Good for the Protective Cytokine Hypothesis , 2004 .

[11]  C. Lewis,et al.  A Genome-Wide Scan for Urinary Albumin Excretion in Hypertensive Families , 2003, Hypertension.

[12]  V. Petrov,et al.  Association between transforming growth factor-β and hypertension , 2003 .

[13]  A. Ferrante,et al.  Relationship between transforming growth factor β1 and progression of hypertensive renal disease , 2002, Journal of Human Hypertension.

[14]  M. Mariani,et al.  Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension , 2002, Journal of Human Hypertension.

[15]  Y. Akai,et al.  Association of transforming growth factor-β1 T29C polymorphism with the progression of diabetic nephropathy , 2001 .

[16]  Yoshiji Yamada,et al.  Association of the C–509→T polymorphism, alone or in combination with the T869→C polymorphism, of the transforming growth factor-β1 gene with bone mineral density and genetic susceptibility to osteoporosis in Japanese women , 2001, Journal of Molecular Medicine.

[17]  Y. Pinto,et al.  Reduction in Left Ventricular Messenger RNA for Transforming Growth Factor &bgr;1 Attenuates Left Ventricular Fibrosis and Improves Survival Without Lowering Blood Pressure in the Hypertensive TGR(mRen2)27 Rat , 2000, Hypertension.

[18]  J. Díez,et al.  Transforming Growth Factor &bgr; in Hypertensives With Cardiorenal Damage , 2000, Hypertension.

[19]  M. Yokota,et al.  Association of a T29-->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. , 2000, Circulation.

[20]  V. Sharma,et al.  Transforming growth factor-β1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage , 2000 .

[21]  J. Bidwell,et al.  Identification of human TGF-beta1 signal (leader) sequence polymorphisms by PCR-RFLP. , 2000, Journal of immunological methods.

[22]  G. Desideri,et al.  High plasma renin activity is combined with elevated urinary albumin excretion in essential hypertensive patients. , 1999, Kidney international.

[23]  J. Gunn,et al.  Transforming growth factor-beta1 gene polymorphisms and coronary artery disease. , 1998, Clinical science.

[24]  F. Pociot,et al.  TGF-beta1 gene mutations in insulin-dependent diabetes mellitus and diabetic nephropathy. , 1998, Journal of the American Society of Nephrology : JASN.

[25]  D. Wilcken,et al.  A common polymorphism of the transforming growth factor-beta1 gene and coronary artery disease. , 1998, Clinical science.

[26]  P. Hasleton,et al.  Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. , 1998, Transplantation.

[27]  K. Kario,et al.  Hypertensive nephropathy and the gene for angiotensin-converting enzyme. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[28]  R. Ravazzolo,et al.  The deletion polymorphism of the angiotensin I-converting enzyme gene is associated with target organ damage in essential hypertension. , 1996, Journal of the American Society of Nephrology : JASN.

[29]  D. Arveiler,et al.  Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Témoin de l'Infarctus du Myocarde (ECTIM) Study. , 1996, Hypertension.

[30]  J. Connell,et al.  Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. , 1995, Hypertension.

[31]  J. Laragh,et al.  Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. , 1995, Journal of the American College of Cardiology.

[32]  G. Dell'omo,et al.  Microalbuminuria and endothelial dysfunction in essential hypertension , 1994, The Lancet.

[33]  M. Ketteler,et al.  Increased expression of transforming growth factor-beta in renal disease. , 1994, Current opinion in nephrology and hypertension.

[34]  K. Borch-Johnsen,et al.  Urinary albumin excretion in a population based sample of 1011 middle aged non-diabetic subjects , 1993 .

[35]  P Corvol,et al.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. , 1990, The Journal of clinical investigation.

[36]  L. Palmer,et al.  Transforming growth factor-beta1 promoter polymorphism C-509T is associated with asthma. , 2004, American journal of respiratory and critical care medicine.

[37]  A. Krolewski,et al.  TGF-beta 1 as a genetic susceptibility locus for advanced diabetic nephropathy in type 1 diabetes mellitus: an investigation of multiple known DNA sequence variants. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[38]  T. Spector,et al.  Genetic control of the circulating concentration of transforming growth factor type beta1. , 1999, Human molecular genetics.

[39]  W. Border,et al.  Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. , 1998, Hypertension.

[40]  J. Ménard,et al.  Vascular angiotensin-converting enzyme expression regulates local angiotensin II. , 1997, Hypertension.